论文部分内容阅读
目的对比分析替吉奥与吉西他滨在老年中晚期非小细胞肺癌治疗中的应用价值。方法搜集2015年1月至2016年2月确诊为中晚期非小细胞肺癌的老年患者45例,随机分为观察组(替吉奥)及对照组(吉西他滨),对比二者疾病控制率、不良反应发生率、KPS评分、PFS等指标,评价二者结果。结果经过治疗后,观察组与对照组患者疾病控制率、KPS评分、PFS时间分别为58.3%和52.3、66.7%和61.0、6.4个月和7.1个月,二组差异无统计学意义(P>0.05)。而不良反应发生率对照组明显高于观察组,具有统计学意义(P<0.05)。结论对于老年中晚期肺癌患者,两组的近期治疗效果、KPS评分、PFS时间等指标无明显的统计学差异,但观察组的不良反应发生率明显低于对照组。
Objective To compare and analyze the value of tegmental and gemcitabine in the treatment of advanced non-small cell lung cancer in the elderly. Methods Forty-five elderly patients with advanced non-small cell lung cancer (NSCLC) diagnosed from January 2015 to February 2016 were randomly divided into observation group (getigat) and control group (gemcitabine) Response rate, KPS score, PFS and other indicators, evaluate the results of both. Results After treatment, the disease control rate, KPS score and PFS in observation group and control group were 58.3% and 52.3%, 66.7% and 61.0, 6.4 and 7.1 months, respectively, with no significant difference between the two groups (P> 0.05). The incidence of adverse reactions in the control group was significantly higher than the observation group, with statistical significance (P <0.05). Conclusion There is no significant difference between the two groups in short-term treatment effect, KPS score and PFS time, but the incidence of adverse reactions in the observation group is significantly lower than that in the control group.